|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquired_by
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:acquisition
|
$62 billion
|
|
gptkbp:acquisition_year
|
gptkb:2019
January 2019
|
|
gptkbp:ceo
|
Christine Carr
|
|
gptkbp:employees
|
over 23,000
over 23,000 (2017)
|
|
gptkbp:founded
|
gptkb:1986
|
|
gptkbp:founder
|
gptkb:Harry_Stratford
|
|
gptkbp:headquarters
|
gptkb:Lexington
gptkb:Dublin,_Ireland
gptkb:United_States
Lexington, Massachusetts, USA
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Shire plc
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:partnerships
|
gptkb:GSK
gptkb:Johnson_&_Johnson
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Abb_Vie
gptkb:Novartis
|
|
gptkbp:previous_name
|
gptkb:Shire_Pharmaceuticals_Group_plc
|
|
gptkbp:products
|
gptkb:Elaprase
gptkb:Lanadelumab
gptkb:Adderall
gptkb:Cerezyme
gptkb:Fabrazyme
gptkb:Intuniv
gptkb:Replagal
gptkb:Vyvanse
Gaucher disease treatments
|
|
gptkbp:related_products
|
gptkb:Elaprase
gptkb:Natpara
gptkb:Cinryze
gptkb:Adynovate
gptkb:Cerezyme
gptkb:Fabrazyme
gptkb:Hemlibra
gptkb:Lialda
gptkb:Myalept
gptkb:Replagal
gptkb:Takhzyro
gptkb:Xiidra
Vpriv
Takeda's pipeline
Veyvondi
|
|
gptkbp:research_areas
|
rare diseases
hematology
neuroscience
gastroenterology
|
|
gptkbp:revenue
|
$15.2 billion (2017)
$15.2 billion (2018)
|
|
gptkbp:specializes_in
|
rare diseases
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
SHPG
|
|
gptkbp:subsidiaries
|
gptkb:Shire_US_Inc.
gptkb:Shire_International_Gmb_H
|
|
gptkbp:website
|
www.shire.com
|
|
gptkbp:bfsParent
|
gptkb:Takeda
|
|
gptkbp:bfsLayer
|
4
|